PRTA
NASDAQProthena Corporation plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$8.91-0.24 (-2.62%)
01:30 PM07:45 PM
News · 26 weeks40+100%
2025-12-072026-05-31
Mix2290d
- Insider11(50%)
- Other6(27%)
- SEC Filings4(18%)
- Earnings1(5%)
Latest news
25 items- INSIDERLarge owner Scully William P bought $471,300 worth of Ordinary Shares (50,000 units at $9.43), increasing direct ownership by 6% to 886,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $981,300 worth of Ordinary Shares (100,000 units at $9.81), increasing direct ownership by 14% to 836,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Welch Daniel G4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Selkoe Dennis J.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Ekman Lars4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Dunn William H. Jr.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooke Shane4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Director Collier Richard T4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERNew insider Scully William P claimed ownership of 868,000 units of Ordinary Shares (SEC Form 3)3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plcSCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
- SECSEC Form 10-Q filed by Prothena Corporation plc10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECProthena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Reports First Quarter 2026 Financial Results and Business HighlightsNet cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche pres
- PRProthena to Report First Quarter 2026 Financial Results on May 7Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 7. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare periphera
- PRProthena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyCoramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participants with ATTR-CM; primary completion expected in 2029 The Fast Track Designation underscores the unmet need within ATTR-CM and could expedite the review of coramitug Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in Phase 3 development for the treatment of ATTR amyloidosis with card
- INSIDERSEC Form 4 filed by Kingston Anne Evans4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kingston Anne Evans3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- PRProthena Announces Leadership Team UpdatesProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer and Michael Isaacs is being promoted to General Counsel and Corporate Secretary. Mr. Isaacs succeeds Michael Malecek who will be departing from Prothena. Ms. Kingston and Mr. Isaacs will join Prothena's leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Ms. Kingston's promotion is effective immediately and Mr. Isaacs' promotion will take effect following Mr. Malecek
- SECSEC Form DEFA14A filed by Prothena Corporation plcDEFA14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECSEC Form DEF 14A filed by Prothena Corporation plcDEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson's disease and BMS-986446 for the treatment of Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online. Roche Presentations on Prasinezumab for the Potential Treatment of Parkinson's Disease Industry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice
- PRProthena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with CardiomyopathyCoramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Novo Nordisk is evaluating coramitug in th
- INSIDERSEC Form 4 filed by Chief Scientific Officer Zago Wagner M.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Walker Karin L4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Swanson Chad J.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
PRTA FAQ
6 questionsWhat does Prothena Corporation plc do?
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other...Where does PRTA stock trade?
Prothena Corporation plc (PRTA) is listed on NASDAQ.What sector and industry is PRTA in?
Prothena Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PRTA?
Prothena Corporation plc has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $400.00 price target on 2025-05-28.What companies are similar to PRTA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PRTA side-by-side with any of them on Quantisnow.How can I track PRTA on Quantisnow?
Quantisnow aggregates Prothena Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRTA to receive live email and push alerts on every new disclosure.